Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.